FDA Women’s Health Initiative Advisory Committee Meeting Postponed
Executive Summary
The Nov. 12-13 meeting of the Women's Health Initiative Subcommittee of FDA's Reproductive Health Drugs Advisory Committee has been postponed
You may also be interested in...
Hormone Therapy Class Labeling Uses Wyeth Template; Appeals Due By March
Sponsors of hormone replacement therapies have two months to pull together data to justify exemptions to FDA's proposed class labeling incorporating risk information from the Women's Health Initiative
Hormone Therapy Class Labeling Uses Wyeth Template; Appeals Due By March
Sponsors of hormone replacement therapies have two months to pull together data to justify exemptions to FDA's proposed class labeling incorporating risk information from the Women's Health Initiative
FDA Reproductive Health Cmte. Line-Up Set; First Priority Will Be WHI Results
The new roster of FDA's Reproductive Health Drugs Advisory Committee includes two members who have conducted research or educational activities on hormone replacement therapy sponsored by Wyeth